10-Q: PACS Group Q2 2025: Strong Revenue Growth, Mounting Legal Woes

PACS Group reported significant revenue and net income increases for Q2 2025, driven by facility expansion, but faces multiple ongoing regulatory and legal investigations, material weaknesses in internal controls, and credit facility forbearance.

Summary

• Total revenue increased by 39.9% to $1.31 billion for the three months ended June 30, 2025, compared to $935.7 million in the prior year, and by 39.4% to $2.59 billion for the six months ended June 30, 2025, compared to $1.86 billion.
• Net income attributable to PACS Group, Inc. saw a substantial turnaround, reaching $50.96 million for the three months ended June 30, 2025, up from a net loss of $31.88 million in the prior year, and $79.44 million for the six months ended June 30, 2025, up from $2.94 million.
• The company's portfolio expanded to 316 facilities across 17 states as of June 30, 2025, an increase of 43.6% from 220 facilities as of June 30, 2024.
• Operational beds increased by 31.6% to 32,208 as of June 30, 2025, from 24,483 in the prior year.
• Overall occupancy rate for skilled nursing services decreased to 88.6% for the three months ended June 30, 2025, from 91.0% in the prior year, primarily due to lower occupancy in New and Ramping facilities.
• Skilled mix by revenue for all facilities decreased to 49.4% for the three months ended June 30, 2025, from 51.2% in the prior year.
• The company identified material weaknesses in its internal control over financial reporting, specifically in its control environment and revenue recognition processes, leading to a conclusion that disclosure controls were not effective as of June 30, 2025.
• PACS Group is subject to multiple ongoing regulatory investigations by the U.S. Department of Justice (DOJ) and the SEC, related to alleged False Claims Act violations, Anti-Kickback Statute, COVID-19 waivers, Medicare Part B billing, and accounting/financial reporting.
• A securities class action lawsuit and two shareholder derivative actions have been filed, alleging a multi-year scheme to inflate revenue and profitability.
• The company entered into multiple forbearance agreements with lenders under its Amended and Restated Credit Facility due to 'technical events of default,' extending the forbearance period to November 30, 2025, and restricting new borrowings.
• Prior period financial statements (Q1 and Q2 2024) were restated due to adjustments related to Medicare Part B revenue and incorrect lease classifications.
• Legal and other costs increased significantly to $24.1 million for the three months and $46.9 million for the six months ended June 30, 2025, primarily due to the Audit Committee's independent investigation and ongoing government investigations.

Sentiment

Score: 3

Explanation: Despite strong revenue and net income growth, the company faces severe underlying issues including material weaknesses in internal controls, multiple ongoing regulatory and legal investigations (DOJ, SEC, class action, derivative suits), and credit facility defaults requiring forbearance. These significant operational and governance challenges overshadow the positive financial performance, indicating substantial risk and uncertainty.

Positives

• Total revenue increased by 39.9% for the three months and 39.4% for the six months ended June 30, 2025, demonstrating strong top-line growth.
• Net income attributable to PACS Group, Inc. significantly improved from a loss of $31.88 million to a gain of $50.96 million for the three months ended June 30, 2025, and from $2.94 million to $79.44 million for the six months ended June 30, 2025.
• The company expanded its operations, increasing the total number of facilities by 34.1% to 287 skilled nursing facilities and 29 assisted/independent living facilities, and operational beds by 31.6% to 32,208.
• Mature facilities showed improved occupancy, increasing by 0.5% to 94.7% for the three months ended June 30, 2025, and by 0.7% to 95.1% for the six months ended June 30, 2025.
• Interest expense decreased by 56.1% for the three months and 56.7% for the six months ended June 30, 2025, due to reduced line of credit and long-term debt balances.
• Cash and cash equivalents increased to $294.2 million as of June 30, 2025, from $157.7 million as of December 31, 2024, with net cash provided by operating activities increasing by $109.3 million.

Negatives

• The company restated its Q1 and Q2 2024 financial statements due to errors in Medicare Part B revenue recognition and incorrect lease classifications, indicating past accounting irregularities.
• Overall occupancy rate for skilled nursing services decreased to 88.6% for the three months and 88.9% for the six months ended June 30, 2025, from 91.0% in the prior year, driven by declines in New and Ramping facilities.
• Skilled mix by revenue for all facilities decreased to 49.4% for the three months and 49.7% for the six months ended June 30, 2025, from 51.2% and 51.6% respectively, indicating a shift towards lower-reimbursement payor sources.
• Average Medicare daily rates decreased by 0.5% for the three months and 0.6% for the six months ended June 30, 2025.
• General and administrative expenses increased by $15.5 million for the six months ended June 30, 2025, primarily due to a $46.9 million increase in legal expenses associated with independent and government investigations.
• The company identified material weaknesses in its internal control over financial reporting, concluding that disclosure controls and procedures were not effective as of June 30, 2025.
• Multiple ongoing regulatory investigations by the DOJ and SEC, along with securities class action and shareholder derivative lawsuits, pose significant legal and financial uncertainty.
• The company is operating under forbearance agreements with its lenders due to 'technical events of default' under its credit facility and master lease, which restricts new borrowings and requires maintaining minimum liquidity.

Risks

• Dependence on reimbursement from third-party payors, with changes in patient acuity, payor mix, payment methodologies, or new cost-containment initiatives potentially reducing revenue and margins.
• Risk of not being fully reimbursed under consolidated billing or bundled payments, adversely affecting financial condition.
• Shortages of nurses and other skilled staff, or heightened competition for such personnel, could increase labor costs and lead to penalties.
• State regulation or deregulation of healthcare services and facility development could restrict growth or intensify competition.
• Failure to attract patients and compete effectively may reduce revenue and profitability.
• Compliance reviews of care, records, and billing may identify issues requiring repayments or other costs.
• Litigation and claims common in the industry could result in significant legal expenses, settlements, damages, or losses under self-insurance programs.
• A material weakness in internal control over financial reporting, or failure to remediate or maintain effective controls, could impair timely, accurate reporting, reduce investor confidence, expose the company to penalties, and harm stock value.
• Inconsistent quality of care or staff misconduct could harm patients, trigger civil or criminal penalties, and damage the business.
• Failures or interruptions in information technology could disrupt operations.
• Operational metrics derived from internal systems may be inaccurate, harming reputation and business.
• Inability to complete acquisitions at attractive prices or at all, and divestitures of underperforming or non-strategic assets could reduce revenue.
• Failure to successfully integrate acquired facilities or realize expected benefits.
• Acquisition activity may entail unforeseen costs, liabilities, or regulatory issues that adversely affect operations.
• Challenges in forming joint ventures aligned with growth strategy.
• Lower CMS or private quality ratings could negatively affect the business.
• Limited availability or higher cost of insurance could adversely affect the company.
• Self-insurance programs may expose the company to significant and unexpected costs.
• Concentration of facilities in certain regions increases vulnerability to local economic downturns, regulatory shifts, or natural disasters.
• Union activity may adversely affect revenue and profitability.
• Risks from lease terminations, renewal negotiations, and special charges due to leasing most facilities.
• Insufficient cash flow for debt, mortgage, or lease obligations could cause defaults and cross-defaults, risking loss of facilities or foreclosures.
• Founders' personal guarantees on certain leases increase default risk to them.
• Need for additional capital to fund operations and growth, which may be unavailable or available only on unfavorable terms.
• Operating in a highly regulated industry, where noncompliance or regulatory change could require significant expenditures or operational changes.
• Founders' majority ownership and related governance arrangements concentrate control, limiting shareholder ability to influence corporate matters.
• As a controlled company under NYSE rules, reliance on governance exemptions may mean stockholders do not have the same protections as stockholders of companies subject to those requirements.

Future Outlook

The company expects patient and resident service revenue to continue increasing as it executes its acquisition strategy. Cost of services and rent-cost of services are also anticipated to rise with business growth. General and administrative expenses are projected to increase in absolute dollar terms but are expected to be leveraged over time as a percentage of revenue. Management believes current cash balances and cash flow from operations will be sufficient for operating needs for at least the next 12 months, but may seek additional capital in the future to fund growth, capital renovations, operations, and other business activities, though availability on acceptable terms is not assured.

Management Comments

• "We believe our significant historical growth has been primarily driven by our expertise in acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care skilled nursing facilities."
• "We believe our success is driven in significant part by our decentralized, local operating model, through which we empower local leaders at each facility to operate their facility autonomously and deliver excellence in clinical quality and a superior experience for our patients."
• "We are in active discussions with the Required Lenders (as defined in the Amended and Restated Credit Agreement) regarding the terms of an amendment and waiver to our Amended and Restated Credit Facility and expect to reach an agreement before the end of the forbearance period to be able to borrow additional amounts."
• "Our management is committed to maintaining a strong internal control environment."

Industry Context

The post-acute care industry is an essential and evolving component of the healthcare delivery ecosystem, driven by an aging population, increasing life expectancies, and a shift towards lower-cost care settings. Skilled Nursing Facilities (SNFs) play a crucial role, providing higher-acuity care at a lower cost than hospitals. The industry is highly fragmented, with approximately 15,000 facilities and 5,000 smaller operators, creating significant acquisition and consolidation opportunities for larger providers like PACS Group. Demand for SNFs is growing, outpacing supply due to stringent regulatory compliance, quality standards, and capital requirements, which act as barriers to entry for new operators. The reimbursement environment is generally favorable, with Medicare and Medicaid rates steadily increasing over the past few years, although the industry remains highly regulated, with providers subject to complex federal, state, and local laws.

Comparison to Industry Standards

• The SNF industry in the United States encompasses approximately 15,000 facilities, with the top 10 operators representing about 11% of the total. PACS Group operates 316 facilities, positioning it as one of the largest providers, suggesting a scale advantage over the fragmented market of smaller, independent operators.
• The industry has seen a decline in the number of SNFs from approximately 15,650 in 2017 to 14,800 in 2024, while demand is growing. PACS Group's expansion strategy, adding 96 net facilities since June 30, 2024, counters this trend and capitalizes on the unmet demand.
• CMS data as of September 2024 indicates approximately 73% of SNFs are for-profit, 21% non-profit, and 6% government-operated. PACS Group's for-profit model aligns with the majority of the industry.
• Medicare and Medicaid reimbursement rates have increased at a CAGR of approximately 3.6% and 1.9% respectively from 2012 to 2021. PACS Group's average Medicaid rates increased by 9.2% (3 months) and 8.3% (6 months) in 2025, outperforming the historical Medicaid CAGR, while Medicare rates slightly decreased, indicating a mixed performance relative to historical industry trends.

Management Changes

Corporate Governance

Legal Proceedings

• **DOJ Civil Investigative Demand (April 8, 2024):** Received by Providence Administrative Consulting Services and Paradise Valley Healthcare Center, investigating potential False Claims Act violations by submitting false claims to Medicare and improper patient referrals in violation of the Anti-Kickback Statute.
• **DOJ Civil Investigative Demand (September 11, 2024):** Received by the company regarding its California-based skilled nursing facilities, investigating potential False Claims Act violations by submitting false claims to Medicare for reimbursement under the patient-driven payment model (PDPM) for skilled nursing and rehabilitation services.
• **DOJ Civil Investigative Demand (September 30, 2024):** Received by Providence Group, Inc. regarding its skilled nursing facilities, specifically Bishop Care Center, investigating potential False Claims Act violations by submitting false claims to Medicare for reimbursement under the COVID-19 related Hospital Stay Waiver (1135 waiver).
• **DOJ Subpoena (February 26, 2025):** Received by the company per HIPAA, investigating possible violations of 18 U.S.C. related to fraudulent or false statements to the U.S. government, specifically concerning 1135 COVID Waiver practices, Medicare Part B respiratory and sensory integration therapy billing, insurance enrollment changes, co-pay/deductible/co-insurance waivers, and Medicare bad debt reimbursement.
• **SEC Investigation:** The SEC's Division of Enforcement is conducting an investigation into matters related to the company's accounting, financial reporting, disclosure, and internal controls over financial reporting and disclosure controls.
• **Securities Class Action (Manchin v. PACS Group, Inc., et al., filed November 13, 2024):** Alleges a multi-year scheme to inflate revenue and profitability by exploiting a COVID-era Medicare waiver, billing unnecessary Medicare Part B therapies, and falsifying licensure and staffing documentation. Consolidated with a similar action, lead plaintiff appointed. Consolidated complaint due 14 days after Q3 2024 10-Q and 2024 10-K filings.
• **Shareholder Derivative Actions (IN RE PACS GROUP, INC. DERIVATIVE LITIGATION, filed February 14, 2025, and Boers v. Murray, et. al., filed August 19, 2025):** Filed against company management, alleging breach of fiduciary duties, unjust enrichment, waste of corporate assets, and contribution, based on substantially similar allegations as the Manchin Action. These actions are currently stayed pending resolution of the anticipated motion to dismiss the securities class action.
• **General Litigation:** The company is subject to other claims and legal actions in the normal course of business, including professional negligence claims, employment-related claims (e.g., wage and hour laws), and COVID-19 related lawsuits. While management does not believe these would have a material adverse effect on results of operations, financial position, or cash flows, outcomes are uncertain and could be material.

Related Party Transactions

• Founders' personal guarantees on certain facility operating leases, increasing their default risk.

Stakeholder Impact

• **Shareholders:** Face potential financial losses due to ongoing legal and regulatory investigations, class action lawsuits, and the uncertainty of their outcomes. The material weaknesses in internal controls could erode investor confidence. Founders' majority ownership concentrates control, limiting influence over corporate matters.
• **Employees:** Subject to potential wage and hour law claims, as well as the impact of operational changes resulting from regulatory compliance efforts and internal control remediation.
• **Patients/Residents:** Directly impacted by the quality of care, billing practices, and staffing levels, which are central to several regulatory investigations and lawsuits. Inconsistent quality of care or staff misconduct could harm patients.
• **Creditors (Lenders):** The company's credit facility is in forbearance due to technical events of default, indicating breaches of loan covenants. This could lead to further restrictions or demands for repayment if an agreement is not reached, impacting the company's financial stability and ability to access capital.
• **Regulatory Authorities:** Actively investigating the company's practices, potentially leading to fines, penalties, sanctions, or changes to business practices, which could have a material adverse effect on operations.

Next Steps

• Continue to implement and advance comprehensive actions to remediate identified material weaknesses in internal control over financial reporting.
• Recruit an experienced candidate to serve as the permanent Chief Compliance Officer and additional compliance, legal, and internal audit personnel.
• Resolve the ongoing discussions with Required Lenders to reach an amendment and waiver agreement for the Amended and Restated Credit Facility before the end of the forbearance period (November 30, 2025).
• Cooperate with all ongoing regulatory investigations by the DOJ and SEC to produce requested information and documentation.
• Vigorously defend against the securities class action and shareholder derivative lawsuits, including responding to anticipated motions to dismiss.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on future financial reports.

Key Dates

Recommendation

Despite strong revenue growth and a return to net profitability, the filing reveals severe and pervasive issues that fundamentally undermine the company's stability and investor confidence. The material weaknesses in internal controls, coupled with a restatement of prior financials, indicate a significant lack of financial reporting integrity. The multitude of ongoing DOJ and SEC investigations, alongside securities class action and shareholder derivative lawsuits, point to potential widespread misconduct and substantial future legal and financial liabilities. Furthermore, the company's credit facility is in forbearance due to technical defaults, restricting its access to capital and highlighting significant covenant breaches. These factors collectively present an extremely high-risk profile, suggesting that the positive top-line performance is unsustainable or at least highly vulnerable to future adverse developments. A seasoned investor would view these systemic issues as a strong indicator to exit the position.

Keywords

Skilled nursing facilities, Post-acute care, Healthcare services, SEC investigation, DOJ investigation, False Claims Act, Anti-Kickback Statute, Medicare, Medicaid, Internal controls, Material weakness, Securities class action, Shareholder derivative action, Credit facility forbearance, Financial restatement, Occupancy rates, Skilled mix, Acquisitions, Corporate governance